Targeted Vascular Restoration

RESTORING THE
INVISIBLE BARRIER.

Developing a first-in-class Smart Molecule platform to repair vascular leakage and restore the endothelial glycocalyx—initially targeting Acute Pancreatitis (AP) to prevent organ failure.

25%+
Require ICU Care

Severe Acute Pancreatitis (AP) patients require critical unit admission.

0%
Mortality Rate in Severe Cases
0M+
Lives To Save
$0B+
Market Potential
The Clinical Crisis

Vascular Leak:
The Silent Killer.

Vascular collapse driven by fluid leakage causes systemic organ failure. Curix targets the Endothelial Glycocalyx to prevent fatal collapse, starting with a breakthrough for Acute Pancreatitis.

Acute Pancreatitis
0

FDA-Approved Direct Targeted Therapies for Vascular Leak

Mechanism of Acute Pancreatitis and Vascular Leak
Pathophysiology Explorer

Understanding Acute Pancreatitis

The pancreas is a vital organ, but when it becomes inflamed, it triggers a cascade leading to life-threatening complications. Our solution targets the critical turning point in this destructive process.

Healthy Pancreas

Produces essential digestive enzymes and insulin for blood sugar regulation.

Acute Pancreatitis

Inflammation causes the pancreas to digest itself, initiating a severe inflammatory response.

Vascular Leakage

Inflammation leads to leaky blood vessels (vascular permeability), causing fluid accumulation and tissue damage.

Our primary intervention site

Multi-Organ Failure

The inflammatory cascade spreads, affecting lungs, kidneys, and heart, leading to organ failure and death.

Targeted Mechanism

Sealing Leakage.
Restoring Integrity.

Smart Activation

Remains inactive in healthy blood; activates only upon encountering vascular inflammatory markers.

Glycocalyx Restoration

Rapidly rebuilds the hair-like protective lining to seal vessel walls and prevent fluid escape.

"By restoring the glycocalyx, we don't just treat the leak; we rebuild the vessel's primary defense system."

Swipe slider to visualize vessel restoration

From Beachhead to Global Impact

Strategic Roadmap

Phase 1: Validation

Acute Pancreatitis

Current Stage: In Vitro. Proving sealing efficacy in microfluidic models.

CURRENT FOCUS
Phase 2: Scaling

Organ Failure

Expanding to treat Septic Shock and AKI across ICU patient populations.

EXPANSION
Phase 3: Platform

Metastasis Blockade

Stopping the spread of cancer by sealing body-wide vascular pathways.

GLOBAL SCALE
Technological Edge

AI-Accelerated
Drug Development.

Curix integrates artificial intelligence across the entire drug development lifecycle to dramatically accelerate discovery, reduce risk, and improve clinical success.

Predictive Intelligence

Replacing trial-and-error to shorten development timelines.

Reduced R&D Costs

Optimizing formulations to lower resource expenditure.

Clinical Success

Transforming biological data into actionable insights for smarter decisions.

"Our AI-driven platform transforms complex biological data into clear, actionable insights—optimizing formulations, predicting outcomes, and guiding smarter clinical decisions."

DATA PROCESSING OPTIMIZED

Join the Future of
Vascular Medicine.

Partner with Curix Therapeutics as we complete in vitro validation and move toward life-saving clinical trials for Acute Pancreatitis.

Contact Development Team